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Abstract
Background: Liarozole fumarate (liarozole – R85246) is a novel compound with characteristics
of both aromatase inhibitor (AI) and a retinoic acid metabolism blocking agent (RAMBA). Our
objective was to determine the effects of liarozole alone or in combination with tamoxifen on the
N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinoma model, as well as on the uterus
in ovariectomized immature rats.
Methods: (1) Tumor burden experiments: Animals bearing one or more tumors greater than 10
mm in diameter were treated for 56 consecutive days with 20 mg/kg or 80 mg/kg of liarozole by
oral gavage, tamoxifen 100 µg/kg by subcutaneous injection, or a combination of liarozole and
tamoxifen. At the end of the treatment period, total cumulative tumor volume as well as retinoic
acid levels were measured. (2) Uterotrophic assay and proliferation experiments: 21-day-old
ovariectomized (OVX) Sprague-Dawley rats were treated with 20 mg/kg or 80 mg/kg of liarozole
by oral gavage, tamoxifen 1 mg/kg by subcutaneous injection, and combination of both for 4
consecutive days. At the end of the treatment period, uterine weight, epithelial lining cell height
and indices of proliferation cell nuclear antigen (PCNA) were measured.
Results: The tumor burden experiments in rats bearing estrogen receptor (ER) positive mammary
tumours showed that liarozole has a marked anti-tumour effect. In combination with tamoxifen,
liarozole had neither an additive nor an antagonistic effect. However, liarozole markedly reduced
the uterotrophic effects induced by tamoxifen.
Conclusion: Liarozole's antitumor effects on ER positive mammary tumors and its protective
effect on the uterus merit further studies to confirm its clinical value in combination with tamoxifen
in ER positive postmenopausal breast cancer. Liarozole and other retinomimetics might also be
suitable chemoprevention drugs in combination with tamoxifen because of their favorable toxicity
profile.
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Background
Liarozole fumarate (R85246) is an imidazole derivative
that inhibits several cytochrome P-450 enzymes, includ-
ing 4-hydroxylase (which metabolizes retinoic acid) and
aromatase, which converts androgens to estrogens in the
human placenta, the ovaries and peripheral tissues [1-3].
Liarozole fumarate acts via at least two mechanisms of
action: 1) as a powerful third generation aromatase inhib-
itor and 2) as a retinoic acid metabolism blocking agent
(RAMBA) [4-7].
Retinoids (compounds including vitamin A and its syn-
thetic and naturally occurring analogs) are key molecules
in cellular proliferation and differentiation [8]. They are
known to have a wide variety of effects on cellular differ-
entiation and homeostasis including both anti-carcino-
genic and anti-tumoral effects [9-16]. However,
prolonged treatment with retinoids is hampered by the
induction of retinoid acid (RA) metabolism resulting in a
rapid fall in intracellular retinoid levels possibly account-
ing for their lack of clinical efficacy. This has led to the
synthesis of a new class of agents called retinoic acid
metabolism blocking agents (RAMBAs), which inhibit the
P450-mediated catabolism of RA, leading to sustained
increases in intracellular tissue and plasma retinoid levels
[17-23].
Tamoxifen is widely used as a single agent for the treat-
ment of both pre- and postmenopausal estrogen receptor
(ER) positive breast cancer [24]. The concept of combin-
ing a retinoid with an antiestrogen is attractive because
active and tolerable agents from both classes are available
and they have different and potentially complementary
mechanisms of action.
Liarozole induces clinical disease response in advanced
breast cancer patients with both heavily pre-treated ER
positive and ER negative disease [25,26]. In view of its two
independent mechanisms of action as a RAMBA and an
AI, and because the toxicities of liarozole and tamoxifen
appear to be non-overlapping, there is a rationale for
investigating the two drugs in combination. We describe
here the effects of liarozole fumarate in combination with
tamoxifen on the N-methyl-N-nitrosourea (MNU)-
induced rat mammary tumour model and in the ovariect-
omized rat.
Methods
Chemicals
The crystalline powder of liarozole (Janssen Research
Foundation, Beerse, Belgium) was dissolved in hydroxy-
propyl-β-cyclodextrin (Janssen Research Foundation,
Beerse, Belgium). Tamoxifen (Sigma Chemical Co., St.
Louis, MO, USA) was formulated in purified olive oil
(Sigma Chemical Co., St. Louis, MO., USA) by first dis-
solving it in a small volume of ethanol and then evaporat-
ing the ethanol under a stream of purified nitrogen to
solubilize the tamoxifen in the olive oil. 17β-estradiol
(Sigma Chemical Co., St. Louis, MO, USA) was dissolved
in 5% ethanol and 95% saline.
Tumor burden experiments
Animal care and use conformed with the Guide to the
Care and Use of Experimental Animals (Canadian Coun-
cil on Animal Care), and the animal protocol was
approved by the University of Toronto Animal Care Com-
mittee. Forty-two-day-old pathogen-free female Sprague-
Dawley rats (Indianapolis, IN, USA) were housed at 24°C
± 2°C at 50% humidity with a 12 h light/dark cycle. They
were acclimatized for 7 days before the start of the experi-
ment with food and water provided ad libitum. At 50 days
of age the animals received an intraperitoneal injection of
50 mg/kg N-methyl-N-nitrosourea (MNU) (Ash Stevens,
Detroit, MI, USA) dissolved in 0.9% NaCl solution acidi-
fied to pH 4 with acetic acid within 20 min of preparation
[27,28]. The mammary glands were palpated at weekly
intervals starting 4 weeks after MNU administration. Ani-
mals bearing one or more tumors greater than 10 mm in
diameter were subsequently randomized to one of 6 treat-
ment groups (15 rats per group), and treated for 56 con-
secutive days. Liarozole and vehicle hydroxypropyl-β-
cyclodextrin were given twice daily by oral gavages.
Tamoxifen and vehicle olive oil were given once daily by
subcutaneous injection. Group 1: controls; Group 2: liar-
ozole 20 mg/kg (L20); Group 3: liarozole 20 mg/kg +
tamoxifen 100 µg/kg (L20+T100); Group 4: liarozole 80
mg/kg (L80); Group 5: liarozole 80 mg/kg + tamoxifen
100 µg/kg (L80+T100); Group 6: tamoxifen 100 µg/kg
(T100). The location of each tumor, the date of its detec-
tion and its size, measured using calipers, were recorded
weekly. Tumor burden was calculated using the formula:
π × L/2 × w/2, mm2 and the total cumulative tumor area
was calculated for each animal. After 8 weeks of treatment,
rats were euthanized with gaseous carbon dioxide.
Retinoic acid analysis
At the time the animals were sacrificed, blood was taken
for plasma retinoic acid (RA) analysis. RA was extracted
from plasma and quantified by UV absorbance after
HPLC separation as previously described [29].
Uterotrophic assay and proliferation experiments
Animal care and use conformed with the Guide to the
Care and Use of Experimental Animals (Canadian Coun-
cil on Animal Care), and the animal protocol was
approved by the University of Toronto Animal Care Com-
mittee.
Immature (21-day-old, 38–45 g) female Sprague Dawley
rats (Indianapolis, IN, USA) were ovariectomized (OVX)BMC Cancer 2007, 7:26 http://www.biomedcentral.com/1471-2407/7/26
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7 days before the start of the experiment. The animals
were housed with their mothers as described above. The
immature animals were acclimatized for 2 days before
being dosed. At 21 days of age the animals were weighed
and randomized to 7 treatment groups (7 rats per group)
and administered one of the following for 4 consecutive
days. Liarozole and vehicle hydroxypropyl-β-cyclodextrin
were given twice daily by oral gavage. Tamoxifen, 17β-
estradiol and vehicle olive oil were given once daily by
subcutaneous injection. Group 1: OVX controls; Group 2:
OVX + 17β-estradiol 10 µg; Group 3: OVX + liarozole 20
mg/kg; Group 4: OVX + liarozole 80 mg/kg; Group 5: OVX
+ tamoxifen 1 mg/kg; Group 6: OVX + liarozole 20 mg/kg
+tamoxifen 1 mg/kg; Group 7: OVX + liarozole 80 mg/kg
+ tamoxifen 1 mg/kg.
Measurement of uterine weight
On day 5 of treatment rats were sacrificed. The uteri were
excised, trimmed free of fat, pierced and blotted to remove
excess fluid. The body of the uterus was cut just above its
junction with the cervix and at the junction of the uterine
horns with the ovaries. The uterus was then weighed (wet
weight) [30].
Uterine histology
10% phosphate buffered formalin-fixed uteri were proc-
essed for conventional paraffin embedding. Cross sec-
tions (4 µm in thickness) were prepared from both horns
of each uterus and stained with hematoxylin and eosin.
Measurement of epithelial lining cell height
Epithelial lining cell height is expressed as a relative meas-
urement based on calibrations in an ocular micrometer
on the microscope. The epithelial height was measured at
a magnification of ×125, using a Quantimet 500 MC auto-
mated image analysis system (Leica Canada). The image
analysis system is attached to an Orthoplan microscope
equipped with a ×25 objective and a JVC color camera.
Proliferation cell nuclear antigen (PCNA)
Immunohistochemical staining of PCNA was performed
using the DAKO LSAB+ kit with peroxidase (DAKO Diag-
nostics Canada Inc. Mississauga, Ontario, Canada)
according to the manufacturer's instructions. Briefly, the
sections were dewaxed in xylene, rehydrated through
graded ethyl alcohol, and treated with retrieval solution
(0.01 M citrate-buffer, pH 6.0) at 95°C for 30 min in a
boiling water-bath. The sections were then cooled to
room temperature for 20 minutes and all subsequent
steps carried out at room temperature. Sections were
treated with 3% hydrogen peroxide to block endogenous
peroxidase activity. The sections were then incubated with
monoclonal antibodies DAKO-PCNA, PC10 (diluted 1:
100) (DAKO Diagnostics Canada Inc. Mississauga,
Ontario, Canada) for 60 min. After washing with phos-
phate-buffered saline (PBS) the streptavidin complex was
applied, then visualized with diaminobenzidine chro-
mogen solution and counterstained with hematoxylin.
The percentage of PCNA nuclei was determined by count-
ing a total number of 300 luminal epithelial cells and 600
stromal and myometrial cells per section. The PCNA
index (PI) is the number of positively staining cells per
100 cells evaluated. The cells were counted at a magnifica-
tion of ×400. Quantitative analysis of immunohistochem-
ical staining of PCNA was performed using the Quantimet
500 MC automated image analysis system (Leica Can-
ada). The image analysis system was attached to an Ortho-
plan microscope and a JVC color camera.
Statistical analysis
Data are expressed as the mean ± standard error of the
mean (SEM). In the tumor burden experiments, a two-
stage linear modeling approach for the analysis of
repeated measures was used for the primary analysis (31).
An auto-regressive (order-1) covariance structure was used
to model the square root transformation of the observed
data (31). Uterotrophic assay and proliferation experi-
ments as well as retinoic acid measurements were ana-
lyzed using a one-way ANOVA with statistical software
(Analyse-it Software, Ltd., UK). Pair-wise comparisons
between groups were performed using Fisher's PLSD post-
hoc test. P-values of less than 0.05 were considered statis-
tically significant.
Results and discussion
Antitumoral effects of liarozole alone or in combination 
with tamoxifen
The mean tumor burden for each treatment group is
shown in Figure 1. At the end of the treatment period, the
average tumor burden area of the L20 (525 mm2), L80
(452 mm2), L20+T100 (117 mm2), L80+T100 (84 mm2)
and T100 (32 mm2) groups, was significantly smaller than
in the control animals (1375 mm2) (all p < 0.05). The
cumulative tumor growth was significantly slower in all
treatment groups compared to the control group (p =
0.0001). Both liarozole and tamoxifen when given alone
demonstrated anti-tumor effects. However, while
tamoxifen lead to tumor shrinkage, liarozole was only
able to stop tumor growth. When given in combination,
liarozole (80 mg/kg) plus tamoxifen (100 mg/kg) was
more effective than liarozole alone (p = 0.0001), Liaro-
zole added to tamoxifen did not alter its anti-tumor effects
significantly (p = 0.23). There were no significant differ-
ences between the two doses of liarozole either when
given alone (p = 0.49) or in combination with tamoxifen
(p = 0.8). RA levels varied from 0.09–0.39 ng/ml but were
not significantly different between any groups.
Combining either letrozole or anastrozole with tamoxifen
lead to a reduction in tamoxifen's anti-tumor effects inBMC Cancer 2007, 7:26 http://www.biomedcentral.com/1471-2407/7/26
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preclinical studies [32]. In addition, the combination of
anastrozole and tamoxifen was less effective than either
agent alone in the large adjuvant ATAC (Anastrozole,
Tamoxifen And Combined) study [33]. In view of these
data the finding that liarozole did not decrease the anti-
tumor effect of tamoxifen in our animal tumor study is of
particular importance.
Uterotrophy and uterine cell proliferation
The effects of liarozole and tamoxifen alone or in combi-
nation on uterine wet weight, epithelial height and PCNA
index were all closely correlated with each other (Figure
2). Figures 3 and 4 show photomicrographs, which dem-
onstrate the effects of the different drugs on epithelial
height and PCNA, respectively. Both estrogen and
tamoxifen alone caused significant increases in uterine
wet weight, uterine epithelial height and PCNA index.
Both doses of liarozole alone had no significant effect on
uterine height, weight or PCNA. When the higher dose of
liarozole (80 mg/kg) was combined with tamoxifen it was
able to significantly reduce tamoxifen's uterotrophic
effects (P < 0.05).
These results are consistent with those of Brodie et al.,
who found that while both letrozole and anastrozole were
able to block the effects of estrogen on the uterus, when
combined with tamoxifen they reduced its stimulatory
effects [32]. It seems that the anti-estrogenic effects of aro-
matase inhibitors are able to completely antagonize the
pro-estrogenic effects of tamoxifen on the endometrium.
Although these data show that the combination of
tamoxifen and an aromatase inhibitor has an improved
toxicity profile compared to tamoxifen, combinations of a
pure aromatase inhibitor clinically with tamoxifen are no
longer being tested because of the data from the ATAC
trial. In contrast to the aromatase inhibitors, our results
Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary  carcinoma and uterus in the rat model Figure 1
Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-
induced mammary carcinoma and uterus in the rat model. Effects of liarozole alone and in combination with 
tamoxifen on tumor burden of MNU-induced rat mammary carcinoma in cycling female Sprague-Dawley rats. Treatment 
groups: controls, liarozole 20 mg/kg (L20), liarozole 80 mg/kg (L80), liarozole 20 mg/kg in combination with tamoxifen 100 µg/
kg (L20+T100), liarozole 80 mg/kg in combination with tamoxifen 100 µg/kg (L80+T100) and tamoxifen 100 µg/kg (T100).
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Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary  carcinoma and uterus in the rat model Figure 2
Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-
induced mammary carcinoma and uterus in the rat model. Effects of liarozole alone and in combination with 
tamoxifen on uterine wet weight (a), uterine epithelial lining cell height (b) and PCNA index (c). Scale bars represent group 
mean ± SEM. Treatment groups: OVX controls, 17β-estradiol 10 µg/kg (E2), liarozole 20 mg/kg (L20), liarozole 80 mg/kg (L80), 
tamoxifen 1 mg/kg (T), tamoxifen 1 mg/kg + liarozole 20 mg/kg (T+L20), tamoxifen 1 mg/kg + liarozole 80 mg/kg (T+L80). *P < 
0.05 versus tamoxifen 1 mg/kg (T).BMC Cancer 2007, 7:26 http://www.biomedcentral.com/1471-2407/7/26
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demonstrate that retinoids do not reduce the SERMs' anti-
tumor effects, offering the possibility to combine these
two classes of agents in the clinical setting.
Conclusion
Liarozole when given alone was able to slow the growth
of tumors in the MNU-induced ER positive rat mammary
tumor model but we were not able to demonstrate an
additive anti-tumor effect of liarozole and tamoxifen.
However, in contrast to other third generation aromatase
inhibitors, we have shown that liarozole does not reduce
tamoxifen's anti-tumor effects. In addition, liarozole is
known to have additional inhibitory effects on ER nega-
tive tumors [26] and it may reverse tamoxifen resistance
[34]. We have also demonstrated that liarozole is able to
reduce the unwanted uterotrophic effects of tamoxifen.
For these reasons, the clinical combination of liarozole
and tamoxifen might be worth evaluating. In particular in
the chemopreventive setting, where two of the main goals
are to limit toxicities and to target both ER positive and ER
negative disease, the combination of these two drugs or
novel SERMS in combination with other retinomimmet-
ics merit further study.
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Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary  carcinoma and uterus in the rat model Figure 3
Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-
induced mammary carcinoma and uterus in the rat model. Hematoxylin and eosin-stained sections of rat uteri illus-
trating epithelial lining cells obtained from the following groups: OVX controls (A), 17β-estradiol 10 µg/kg (B), liarozole 80 mg/
kg (C), tamoxifen 1 mg/kg (D) and liarozole 80 mg/kg + tamoxifen 1 mg/kg (E). Note the inhibitory effect of liarozole signifi-
cantly negated the tamoxifen stimulatory effect on the epithelial cells (bar in E = 50 µm).BMC Cancer 2007, 7:26 http://www.biomedcentral.com/1471-2407/7/26
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Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary  carcinoma and uterus in the rat model Figure 4
Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-
induced mammary carcinoma and uterus in the rat model. Immunohistochemical staining for PCNA in the uterus of 
rats obtained from OVX controls (A), 17β-estradiol 10 µg/kg (B), liarozole 80 mg/kg (C), tamoxifen 1 mg/kg (D) and liarozole 
80 mg/kg + tamoxifen 1 mg/kg (E). Note the inhibitory effect of liarozole significantly negated the tamoxifen stimulatory effect 
on the PCNA staining (magnification, ×400).BMC Cancer 2007, 7:26 http://www.biomedcentral.com/1471-2407/7/26
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